Table 1.
Baseline characteristics.
Fig 1.
Abbreviations: SS, standard setting; DOT, directly observed therapy; SVR, sustained virologic response; LTFU, lost to follow-up. a at week 12 after end of therapy. b 16 weeks after end of treatment for reasons not related to therapy.
Table 2.
Socioeconomic characteristics of study patients at baseline.
Fig 2.
SVR12 rates after treatment with G/P according to mITT.
Abbreviations: SVR, sustained virologic response; G/P, glecaprevir/pibrentasvir; mITT, modified intention-to-treat; SS, standard setting; DOT, directly observed therapy; LTFU, lost to follow-up; HCV, hepatitis C virus; GT, genotype. A—All patients (n = 141/145). a including one patient who died 16 weeks after end of therapy for reasons not related to treatment after showing a negative HCV-RNA PCR result three weeks after end of therapy. B—Patients with advanced fibrosis (n = 21/21). Advanced fibrosis was defined as F3-F4: ≥9.5 kPa according to transient elastography. C—Patients with HCV GT3 infection (n = 54/56).